Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab is being evaluated as ...

Merck is discontinuing the KeyVibe-003 and KeyVibe-007 studies evaluating the fixed-dose combination of vibostolimab, an anti-TIGIT antibody and Keytruda in a non-small cell lung cancer (NSCLC ...

About KeyVibe-007 KeyVibe-007 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT05226598) evaluating the fixed-dose combination of vibostolimab and pembrolizumab with ...

Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell ...

KeyVibe-007 is a randomized, double-blind phase 3 trial (ClinicalTrials.gov, NCT05226598 ) evaluating the fixed-dose combination of vibostolimab and pembrolizumab with chemotherapy in treatment-naïve ...

Vibostolimab was being tested as part of a fixed-dose combination with Merck's megablockbuster oncology drug Keytruda in a pair of phase 3 trials, dubbed KeyVibe-003 and KeyVibe-007.

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose com Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis Skip to ...

Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell ...

Merck is discontinuing the phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...

Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program. Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which ...